WAVE Life Sciences (NASDAQ:WVE) Stock Price Expected to Rise, Wedbush Analyst Says

WAVE Life Sciences (NASDAQ:WVE) had its price target hoisted by investment analysts at Wedbush from $33.00 to $35.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 166.77% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Leerink Partners reissued an “outperform” rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Morgan Stanley set a $28.00 price objective on shares of WAVE Life Sciences in a research note on Monday, December 8th. Oppenheimer lifted their target price on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Cantor Fitzgerald boosted their target price on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Wells Fargo & Company decreased their price target on WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Thursday, February 12th. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, WAVE Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.13.

WAVE Life Sciences Price Performance

WAVE Life Sciences stock opened at $13.12 on Friday. The firm has a market capitalization of $2.47 billion, a P/E ratio of -10.75 and a beta of -1.77. The stock has a fifty day moving average price of $14.00 and a two-hundred day moving average price of $10.95. WAVE Life Sciences has a 52-week low of $5.28 and a 52-week high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last issued its earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The firm had revenue of $17.25 million during the quarter, compared to analyst estimates of $15.68 million. On average, equities research analysts predict that WAVE Life Sciences will post -1.14 EPS for the current fiscal year.

Insider Activity

In other news, insider Chris Francis sold 33,194 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the transaction, the insider directly owned 61,867 shares in the company, valued at approximately $931,098.35. This represents a 34.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Chandra Vargeese sold 3,228 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $43,416.60. Following the sale, the insider directly owned 408,246 shares in the company, valued at $5,490,908.70. This trade represents a 0.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 948,375 shares of company stock worth $14,112,151. 23.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of WVE. GSK plc bought a new position in WAVE Life Sciences in the 4th quarter valued at $310,177,000. Darwin Global Management Ltd. bought a new stake in shares of WAVE Life Sciences during the fourth quarter worth $125,168,000. Federated Hermes Inc. raised its position in shares of WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock worth $27,455,000 after acquiring an additional 3,750,140 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of WAVE Life Sciences by 83.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after acquiring an additional 3,362,880 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after acquiring an additional 2,500,000 shares during the period. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wedbush raised its price target on WVE to $35 and reiterated an “outperform” rating — a bullish signal implying substantial upside versus the current price and likely supporting buy-side interest. Wedbush price target raise
• Positive Sentiment: HC Wainwright increased near-term EPS estimates across Q1–Q4 2026 and kept a “Buy” rating with a $30 target, signaling improving analyst sentiment on WAVE’s financial outlook. (Research note summarized in market coverage.)
• Positive Sentiment: Wave announced acceptance of a late‑breaking oral presentation for WVE‑006 (GalNAc‑RNA editing) at the American Thoracic Society conference — new data from the RestorAATion‑2 trial (400 mg multidose and 600 mg single‑dose cohorts) will be presented, which could materially move the stock depending on the clinical readout. ATS presentation acceptance
• Neutral Sentiment: Analysts’ long‑range earnings expectations were updated in a report setting FY2029 estimates — useful for modeling but unlikely to drive immediate price moves absent near‑term catalysts. Analyst expectations for FY2029
• Negative Sentiment: A CNBC piece highlighted recent FDA reversals and heightened regulatory scrutiny across biotech (citing multiple denials and reversals), which has increased sector volatility and likely weighed on WVE shares despite company‑specific positives — investors are more sensitive to regulatory risk today. FDA reversals raise sector concerns

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.